# An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)

> **NCT01202058** · PHASE3 · TERMINATED · sponsor: **Cordis US Corp.** · enrollment: 156 (actual)

## Conditions studied

- Atherosclerotic Coronary Artery Disease

## Interventions

- **DEVICE:** NEVO™ Sirolimus-eluting Coronary Stent System
- **DEVICE:** XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)

## Key facts

- **NCT ID:** NCT01202058
- **Lead sponsor:** Cordis US Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2011-11
- **Final completion:** 2012-10
- **Target enrollment:** 156 (ACTUAL)
- **Why stopped:** The NEVO™ stent will not be commercialized. Cordis decided to close the study after 1 years. This decision took the absence of safety signals into account.
- **Last updated:** 2012-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202058, "An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01202058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*